8-K/A: Shineco, Inc. Amends 8-K to Detail Financials of Acquired iPSC Technology Firm InfiniClone Limited

Shineco, Inc. has filed an amended 8-K to provide the required financial statements for its recently acquired 51% equity interest in InfiniClone Limited, an iPSC technology company, detailing the acquisition's financial impact and InfiniClone's historical performance.

Summary

• Shineco, Inc. (SISI) completed the acquisition of a 51% equity interest in InfiniClone Limited on June 18, 2025, through its subsidiary Shineco Life Science Group Hong Kong Co., Limited.
• The acquisition consideration totaled an estimated fair value of US$24,035,600, comprising US$19,895,600 in cash and 3,450,000 shares of Shineco's common stock.
• InfiniClone Limited, a Hong Kong-based company, specializes in research, development, and commercialization of induced pluripotent stem cell (iPSC) technology, including iPSC banking, cosmeceutical applications, disease modeling, regenerative medicine, drug discovery, and next-generation stem cell therapy.
• InfiniClone reported no revenue for the fiscal years ended June 30, 2024, and 2023, and for the nine months ended March 31, 2025 and 2024.
• InfiniClone incurred a net loss of US$367,421 for the year ended June 30, 2024, and a net loss of US$759,929 for the nine months ended March 31, 2025.
• InfiniClone's total assets significantly increased to US$23,150,980 as of June 30, 2024, from US$1,569 in 2023, primarily due to the transfer of 8 properties valued at US$23,595,506 and R&D materials valued at US$502,695, both paid through the issuance of InfiniClone's shares.
• The pro forma combined financial statements show a net loss of US$23,751,378 for the nine months ended March 31, 2025, and US$26,744,870 for the year ended June 30, 2024, for the combined entity.
• The preliminary purchase price allocation for InfiniClone includes identifiable intangible assets of approximately US$24,170,000 (patent technology) and goodwill of US$1,736,248.

Sentiment

Score: 3

Explanation: While the acquisition of InfiniClone Limited represents a strategic entry into the iPSC technology sector, the financial performance of InfiniClone is currently very weak, characterized by zero revenue and increasing net losses. The low cash balance of InfiniClone and the substantial pro forma losses for the combined entity indicate significant financial challenges and a high cash burn rate, outweighing the strategic potential in the short to medium term.

Positives

• Acquisition of InfiniClone Limited expands Shineco's strategic focus into the promising induced pluripotent stem cell (iPSC) technology sector, including iPSC banking, regenerative medicine, and drug discovery.
• InfiniClone possesses significant assets, including US$22,659,382 in property and equipment and US$490,518 in inventories as of June 30, 2024, indicating a substantial operational base for its R&D activities.
• The acquisition introduces valuable intellectual property, with approximately US$24,170,000 allocated to identifiable intangible assets, primarily exclusive and non-exclusive patent technology.

Negatives

• InfiniClone Limited has not generated any revenue for the fiscal years ended June 30, 2024 and 2023, nor for the nine months ended March 31, 2025 and 2024, indicating it is currently a pre-revenue company.
• InfiniClone reported significant net losses, increasing from US$587 for the year ended June 30, 2023, to US$367,421 for the year ended June 30, 2024, and further to US$759,929 for the nine months ended March 31, 2025.
• General and administrative expenses for InfiniClone increased substantially, from US$389 in 2023 to US$367,421 in 2024, and to US$759,929 for the nine months ended March 31, 2025.
• InfiniClone's cash balance is very low, at US$649 as of March 31, 2025, and US$710 as of June 30, 2024, raising concerns about its liquidity for ongoing operations without external funding.
• The pro forma combined entity shows substantial net losses, with US$23,751,378 for the nine months ended March 31, 2025, and US$26,744,870 for the year ended June 30, 2024.

Risks

• **Going Concern Uncertainty:** InfiniClone's financial statements are prepared assuming it will continue as a going concern, but the company has a history of losses and no revenue, which is a significant negative indicator for the realization of deferred income tax assets.
• **Concentration of Credit Risk:** Substantially all of InfiniClone's cash at bank is held by third-party financial institutions in Singapore, with deposits insured up to SGD 75,000, exposing the company to credit risk beyond this insured amount.
• **Reliance on Related Parties:** InfiniClone has significant related party transactions, including purchases of assets and materials paid through shares, and outstanding balances due to and from related parties, which could pose governance and financial risks.
• **Preliminary Valuation Risk:** The purchase price allocation for the acquisition is preliminary and based on estimates, with no assurance that the finalization will not result in material changes to the pro forma financial information, potentially leading to higher depreciation/amortization or goodwill impairment charges.
• **Lack of Revenue Generation:** InfiniClone is a pre-revenue company, and its ability to generate future taxable income to utilize deferred tax assets is uncertain, given its cumulative loss position.

Future Outlook

The document primarily provides historical and pro forma financial statements related to the InfiniClone acquisition. It notes that the preliminary purchase price allocation is subject to change and that actual results may differ materially from the pro forma amounts due to various factors, including final valuation analysis and changes in operating results.

Management Comments

• Management is responsible for these financial statements.
• In the opinion of the management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of March 31, 2025 and June 30, 2024, the results of operations and cash flows for the nine months ended March 31, 2025 and 2024, have been made.
• Management has considered subsequent events through the reporting day, which was the date the financial statements were issued. No subsequent events required adjustments to or disclosure in these financial statements.

Industry Context

The acquisition of InfiniClone Limited positions Shineco, Inc. to enter or expand its presence in the rapidly evolving induced pluripotent stem cell (iPSC) technology market. This sector is a significant area of innovation in biotechnology, with applications spanning regenerative medicine, drug discovery, and cosmeceuticals. The move aligns with a broader industry trend of diversification and investment into high-growth, research-intensive areas within life sciences, aiming to capture future market opportunities in advanced therapies and bio-manufacturing.

Comparison to Industry Standards

• InfiniClone's current pre-revenue status and significant operating losses are common for early-stage biotechnology companies focused on extensive research and development, particularly in complex fields like iPSC technology, where commercialization can take many years and require substantial upfront investment.
• The substantial increase in InfiniClone's assets, particularly property and equipment (US$22.66 million) and intangible assets (US$24.17 million preliminary fair value), suggests a significant investment in infrastructure and intellectual property, which is typical for companies aiming to establish a strong foundation in capital-intensive R&D sectors.
• The high general and administrative expenses relative to zero revenue indicate a company in a heavy investment phase, building operational capacity before market entry, which is not unusual for a biotech startup but requires careful monitoring of cash burn.

Legal Proceedings

• In the normal course of business, InfiniClone Limited is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, and non-income tax matters.

Related Party Transactions

• InfiniClone Limited's controlling shareholder is Lim Kah Meng. Other related parties include Seah Siew Leng (related person of controlling shareholder), Zenzic Labs Pte. Ltd., Go Dx, and Gene Oasis Pte Ltd. (entities controlled by controlling shareholder).
• On November 15, 2023, InfiniClone purchased lands and buildings amounting to US$6,453,082 from related parties, with consideration paid through the issuance of InfiniClone's shares.
• On December 1, 2023, InfiniClone purchased R&D materials amounting to US$502,695 from a related party, with consideration paid through the issuance of InfiniClone's shares.
• On March 31, 2025, InfiniClone entered into an intellectual property and technology authorization agreement with a related party, incurring a license fee of US$17,767.
• InfiniClone had outstanding balances due to related parties of US$20,174 as of March 31, 2025 (US$2,223 as of June 30, 2024), primarily from Go Dx (US$2,241) and Zenzic Labs Pte. Ltd. (US$17,933).
• InfiniClone had outstanding balances due from related parties of US$374 as of March 31, 2025 (US$370 as of June 30, 2024), primarily from Lim Kah Meng for advances related to share capital payment.

Stakeholder Impact

• **Shareholders (Shineco):** The acquisition introduces a new strategic direction in iPSC technology but also brings a pre-revenue, loss-making entity, which will contribute to significant pro forma net losses and potentially dilute existing shareholder value through share issuance for the acquisition. The preliminary nature of the valuation adds uncertainty.
• **Shareholders (InfiniClone Dr. Lim Kah Meng):** The sole shareholder of InfiniClone received a substantial cash payment (US$19,895,600) and Shineco shares (3,450,000), indicating a significant liquidity event and a stake in the acquiring public company.
• **Employees (InfiniClone):** The acquisition by a larger public company could provide more stable funding and resources for InfiniClone's R&D activities, potentially benefiting employees through continued employment and expanded opportunities.
• **Creditors:** The acquisition and the pro forma financial statements provide a clearer picture of the combined entity's financial position, which could impact creditors' assessment of risk. The increase in total liabilities for the combined entity is notable.

Next Steps

• Shineco, Inc. will integrate InfiniClone Limited's operations and iPSC technology into its business.
• Shineco, Inc. will finalize the detailed valuation analysis and purchase price allocation for the InfiniClone acquisition.
• InfiniClone Limited will continue its research and experimental development and commercialization efforts in iPSC technology.
• Management will need to address the going concern assumption for InfiniClone, given its current pre-revenue status and cumulative losses.

Key Dates

Recommendation

Keywords

SEC Filing, 8-K/A, Shineco Inc, SISI, InfiniClone Limited, Acquisition, iPSC Technology, Stem Cell Therapy, Biotechnology, Financial Statements, Pro Forma, Corporate Governance, Risk Management, SEC Disclosure, Merger and Acquisition, Life Science, Research and Development, Patent Technology, Goodwill, Related Party Transactions